Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2016-10-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Quarterly Shareholder Update - September 2016 8 pages 388.7KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – September 2016' and contains detailed information about the company's drug development pipeline, clinical trials, regulatory approvals, and corporate updates for the quarter ending September 2016. It includes substantive business progress and operational details rather than just a brief announcement or a presentation. The length is about 15,000 characters, indicating a comprehensive report rather than a short notice. The content aligns with a quarterly report providing financial and operational updates for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2016
2016-10-27 English
Appendix 4C - quarterly 5 pages 101.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the quarter ended 30 September 2016. It includes operating, investing, and financing cash flows, reconciliation of cash and cash equivalents, payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The document is 8319 characters long, which is substantial and contains actual financial data and analysis for a quarterly period. This matches the definition of an Interim / Quarterly Report (IR), which must contain substantive financial data and analysis for a period shorter than a full fiscal year. The document is not merely an announcement or certification but a full quarterly financial report. Therefore, the correct classification is IR with high confidence. Q1 2017
2016-10-27 English
Annual Report to shareholders 68 pages 593.9KB
Annual Report Classification · 100% confidence The document is titled 'STATUTORY ANNUAL REPORT 2016' and includes detailed sections such as Directors' Report, Remuneration Report, Corporate Governance, Senior Management, Operating and Financial Review and Prospects, and Financial Statements. It references the financial year ended 30 June 2016 and contains comprehensive financial data including income statements, balance sheets, cash flows, notes to financial statements, and auditor's report. The length of the document is substantial (15,000 characters), indicating it is the full report rather than an announcement. The content matches the characteristics of an official yearly report covering company activity and full financial performance, which aligns with the definition of an Annual Report (10-K). FY 2016
2016-10-25 English
Appendix 4G - Key to Disclosures 13 pages 98.9KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures that must accompany the annual report. It includes a detailed key to disclosures against the ASX Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2016. The document is a formal corporate governance statement approved by the board and lodged with the ASX concurrently with the annual report. It does not contain financial statements or detailed financial performance data but focuses on governance practices and compliance with governance recommendations. This type of document is a corporate governance statement, which is distinct from the full annual report (10-K) or management reports. Given the content and regulatory references, the document fits best under the category 'Governance Information' (CGR). The document length (15,000 characters) and detailed governance disclosures support this classification with high confidence.
2016-10-25 English
Copy of Corporate Governance Statement 17 pages 83.1KB
Governance Information Classification · 100% confidence The document is titled 'Pharmaxis Ltd Copy of Corporate Governance Statement – 2016' and contains detailed descriptions of the company's corporate governance framework, board responsibilities, committee structures, director independence, diversity policies, and performance evaluation processes. It references the ASX Corporate Governance Principles and Recommendations and provides extensive governance-related disclosures. There is no indication that this is an announcement or a brief summary; the content is substantive and focused on governance practices rather than financial results or management changes. Therefore, this document fits the definition of a Governance Information report (CGR), which details the company's internal rules, board structure, and governance practices.
2016-10-25 English
Notice of Annual General Meeting/Proxy Form 10 pages 459.0KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF THE 2016 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT OF PHARMAXIS LTD' and includes details about the date, time, and location of the AGM, proxy voting instructions, agenda items such as financial statements, remuneration report, re-election of a director, and grant of securities. It also contains explanatory notes about voting restrictions and procedures. The document does not contain the actual financial statements or reports but refers to them and provides information for shareholders to participate in the AGM. This matches the description of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document is lengthy (15,000 characters) and detailed, consistent with an AGM notice and explanatory statement rather than a brief announcement or proxy solicitation only. Therefore, the correct classification is AGM Information (AGM-R).
2016-10-25 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.